A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), metastatic triple negative breast cancer ("mTNBC") and Chronic Myelomonocytic Leukemia ("CMML"). Our clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -46M | -46M | -45M | -41M | -39M | -28M |
| EPS | $-0.69 | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 |
| Free Cash Flow | -38M | -38M | -38M | -31M | -35M | -23M |
| ROIC | -134.5% | -71.5% | -54.8% | -59.5% | -36.4% | -20.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -49M | -49M | -49M | -45M | -40M | -29M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -101.1% | -71.5% | -54.8% | -59.5% | -36.4% | -20.2% |
| Shares Outstanding | 66M | 66M | 48M | 45M | 44M | 39M |
Cardiff Oncology, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Cardiff Oncology, Inc. (CRDF) has a 5-year average return on invested capital (ROIC) of -48.5%. This is below average and may indicate limited pricing power.
Cardiff Oncology, Inc. (CRDF) has a market capitalization of $106M. It is classified as a small-cap stock.
Cardiff Oncology, Inc. (CRDF) does not currently pay a regular dividend.
Cardiff Oncology, Inc. (CRDF) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Cardiff Oncology, Inc. (CRDF) generated $-38 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Cardiff Oncology, Inc. (CRDF) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Cardiff Oncology, Inc. (CRDF) reported earnings per share (EPS) of $-0.69 in its most recent fiscal year.
Cardiff Oncology, Inc. (CRDF) has a return on equity (ROE) of -71.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for Cardiff Oncology, Inc. (CRDF), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cardiff Oncology, Inc. (CRDF) has a book value per share of $0.68, based on its most recent annual SEC filing.